The osteoblast-secreted receptor of activated NF-κB (RANK) ligand (RANKL) activates RANK receptors on osteoclasts to promote their differentiation, maturation and survival, and bone resorption [ 1].
The present data on the increased RANK-L expression by RA neutrophils, together with the presence of neutrophils at the pannus-bone interface [ 34], suggest that through cell-cell interactions such inflammatory neutrophils could activate RANK-expressing osteoclasts and bone resorption.
As a result, our scheduling periodically activates one rank after another to optimize memory power efficiency.
Upon ligand stimulation, receptors such as LT βR, BR3, CD40, and receptor activator of nuclear factor kappa B (RANK) activate the NF- κB inducing kinase (NIK) leading to the activation of IKK α homodimer (lacking IKK γ).
Animal models also showed that RANKL-expressing PCa cells conferred bone colonizing and aggressive phenotypes to neighboring non-metastatic bystander cells by activating the RANK-mediated downstream signaling network.
Binding of RANKL to its receptor, Receptor activator of nuclear factor-kappa B (RANK) activates molecules such as NF-kappa B, mitogen activated protein kinase (MAPK), nuclear factor of activated T cells (NFAT) and phosphatidyl 3-kinase (PI3K).
It exerts its functions by binding and activating its receptor RANK [4], [5], which is expressed on the surface of osteoclastic precursors and mature osteoclasts [6].
Denosumab prevents RANKL from activating its receptor, RANK, on the surface of osteoclasts, and reduces bone resorption, tumor-induced bone destruction, and SREs.
First, Krauthammer et al. 47 reported that somatic activating Rac1 mutations, ranking third after BRAF- and NRAS-mutations, in general, occur significantly more often in men than in women.
RANK-RANKL binding activate downstream target genes (TRAF6, NF- κβ, and C-fos) in RANK signaling pathway [ 4, 7, 8].
